Ophthalmology is favored by fund managers. How to interpret the market outlook?

Ophthalmology is favored by fund managers. How to interpret the market outlook?

With the intensive disclosure of mid-year reports of listed companies, some "top-stream" positions have also attracted market attention. In the second quarter, Zhang Kun returned to the top ten tradable shareholders of "Eye Hair" Aier Ophthalmology, and Gulen received more attention, and the leader in the field of pharmaceutical segmentation received attention. So today, Bian Xiao is here to sort out the related knowledge of ophthalmology and medical care for everyone. Let's have a look!

Zhang Kun Masukura's Eye Hair

Zhang Kun, who is known as "a brother in public offering", significantly reduced his holdings of Hikvision in the second quarter of this year, but at the same time significantly increased his holdings of Focus Media and Aier Ophthalmology.

On the evening of August 24th, the latest announcement of Aier Ophthalmology showed that E Fund Blue Chip, managed by Zhang Kun, has become the top ten tradable shareholders of the company, holding 27000438+00000 shares with a market value of/kloc-0.09 million yuan.

Aier Ophthalmology used to be Zhang Kun's "Heart Water Unit". According to the third quarterly report in 2020, E Fund Blue Chip selected 32 million new shares of Aier Ophthalmology at that time, with a stock market value of 65.438+64.5 million yuan. According to the 2020 annual report, E Fund's blue-chip selected position, Aier Ophthalmology, remained unchanged, but its market value rose to 2.396 billion yuan.

In the first quarter of 2002/Kloc-0, Zhang Kun significantly reduced its positions in Aier Ophthalmology, and the number of shares held by E Fund Blue Chip Select in Aier Ophthalmology decreased from 32 million shares at the end of 2020 to 20 million shares at the end of 200211. However, E Fund Blue Chip Select increased its holding of Aier Ophthalmology 15007800 shares in the second quarter of 2002/KLOC-0, and its shareholding increased to 35007900 shares.

In the second half of 200212002, with the continuous decline in the share price of Aier Ophthalmology, Zhang Kun reduced its holdings of Aier Ophthalmology by clearance. According to the annual report published by E Fund Blue Chip Select 202 1, at the end of 20021,the fund only held 200,000 shares of Aier Ophthalmology. In fact, by the end of the third quarter of 20021,E Fund Blue Chip Selection had withdrawn from the top ten tradable shareholders of Aier Ophthalmology. According to the disclosure standards of the top ten tradable shareholders, Zhang Kun reduced his shareholding in the third quarter.

Besides, among the top ten tradable shareholders of Aier Ophthalmology, there are also the figures of China Europe Fund Manager Gu Lun, Huabao Fund Manager hujie and Guangfa Fund Manager Wu. CEIBS Healthcare, managed by Gü len, has been holding Aier Ophthalmology for eight quarters, and in the process of holding it, Gü len has basically been increasing its holdings, especially in the process of the stock price falling in the third and fourth quarters of 2002/KLOC-0. At present, Aier Ophthalmology has become the largest medical and health heavyweight in China and Europe, with a market value of 7187 million yuan.

The semi-annual report of Aier Ophthalmology shows that the operating income in the first half of 2022 was about 865,438+0.07 million yuan, a year-on-year increase of 65,438+00.34%; The net profit attributable to shareholders of listed companies was about 65,438+0.291billion yuan, up 65,438+0.573% year-on-year.

In the case that Zhang Kun, Gulen and other "Top Stream" collectively increased their holdings, the share price of Aier Ophthalmology ushered in an obvious rebound in the second quarter of this year, with a cumulative increase of 42.08% during the period, recovering all the declines in the first quarter. After entering the second half of the year, the share price of Aier Ophthalmology was relatively weak, with a drop of nearly 20% since July.

Glen pays attention to subdividing industry leaders.

The position dynamics of 100 billion "top flow" Gulen is also the focus of market attention. In recent years, Gulen not only pays attention to innovative drugs, medical devices and other tracks, but also is the industry leader in the field of Chinese medicine and medicine segmentation.

On the evening of August 24th, the semi-annual report released by shares showed that CEIBS Healthcare managed by Gü len became the top ten tradable shareholders of the company, holding 870,900 shares at the end of the second quarter, with a stock market value of 64 million yuan.

Adoption shares gradually expanded from the field of veterinary equipment at the beginning of its establishment to the plate of medical equipment and laboratory consumables, and the production scale gradually increased. It has become a leading enterprise of puncture and injection equipment, providing products such as puncture and injection and laboratory consumables to global medical enterprises through ODM/OEM, and its export income in 20021year accounts for more than 90%.

Up to now, China-Europe medical health has been established in Aier Ophthalmology, WuXi PharmaTech, Mindray Medical, Pien Tze Huang, Tongce Medical, Jiuzhou Pharmaceutical, Boteng, Opcom, Huadong Medicine, Medici, Hengrui Pharma, Shi Yao Science and Technology, Gongdong Medical, China Resources Sanjiu, Aladdin, Nanotechnology, Yao Kang Biology, Novo Zhiyuan, Baicheng Medicine and so on.

Among them, the specific positions of Aier Ophthalmology, Wuxi PharmaTech, Mindray Medical, Pien Tze Huang, Tongce Medical and Jiuzhou Pharmaceutical were listed in the second quarterly report of the Fund. The shares of Boteng, Opcom, Huadong Medicine, Medici, Hengrui Pharma, Shi Yao Science and Technology, Gongdong Medical, China Resources Sanjiu, Aladdin, Na Wei Science and Technology, Yao Kang Bio, Nuohe Zhiyuan, Baicheng Medicine and Adoption are disclosed in the semi-annual reports of listed companies.

During the second quarter, Gulen still increased his holdings of related stocks in the sectors of medicine, medical care and traditional Chinese medicine, including Huadong Pharmaceutical, Boya Bio, Opcom, etc. At the same time, China Europe Medical Health also entered the top ten tradable shareholders of China Resources Sanjiu, Yao Kang Bio and adopted shares. ..

Looking ahead to the market outlook, Gulen believes that innovation-related markets are far from touching the ceiling of the domestic market, and overseas markets are gradually accumulating strength. Specific to the company level, the trend of enterprise transformation and innovation is still continuing, and the number of clinical applications for innovative drugs has reached a new high year by year. In terms of innovation quality, in recent years, the overall layout of R&D pipelines has become more reasonable, resources have tilted in the direction of differentiation, and even innovative varieties with global competitiveness have been born.

"In addition, with the rapid improvement of the per capita income and cognitive level of Chinese residents, the demand for medical services and consumer medical care is still growing rapidly, which has not been fully met, and the future space is still huge. On the whole, we are still optimistic about the medium and long-term investment opportunities in the pharmaceutical bio-sector, but short-term market fluctuations are inevitable. "

Zhu Shaoxing obviously adjusted his position.

In the second quarter, the market fluctuated greatly, and Zhu Shaoxing made a substantial adjustment to its invisible heavyweight stocks.

On the evening of August 24th, the semi-annual report of Hangyang Co., Ltd. showed that Guo Fu Tianhui Select managed by Zhu Shaoxing reduced its holdings by 3.371.7 million shares in the second quarter and by the end of the second quarter, it reduced its holdings to 1.9 million shares, with a market value of 594 million yuan.

The reporter combed the stocks selected by Guo Fu Tianhui and found that during the second quarter, Zhu Shaoxing made a substantial adjustment to his positions, and Fuling Zhacai and Hangyang shares were greatly reduced, while most of Jerry shares, Baoxin Software, Wanrun shares, Huali Group, Hudian shares and Feng Chun Electric Power were increased.

In addition, Guo Fu Tianhui Select managed by Zhu Shaoxing has also newly entered the top ten tradable shareholders of Waterproof Maodong Dongfang Yuhong, Yangguang Nuohe and Shandong Heda, among which the market value of Dongfang Yuhong's position reached 65.438+0.45 billion yuan, making it the seventh largest awkward stock at the end of the second quarter. At the end of the first quarter of this year, Guo Fu Tianhui selected and held Oriental Yuhong16,245,800 shares, making it the tenth largest awkward stock. In the second quarter, Guo Fu Tianhui Select increased its holdings of 4,064,200 shares of Oriental Yuhong to 20,365,438+0,000 shares.

However, after Zhu Shaoxing bought Oriental Yuhong in a heavy position, the company's share price began to fall all the way from July. On August 22nd, Oriental Yuhong announced the semi-annual report. Net profit in the first half of the year decreased by 37% year-on-year. The company's share price fell on August 23, and continued to fall on August 24, closing down 2.27%, hitting a new low.

Zhu Shaoxing believes that "the leading valuation of the traditional sector is in an attractive position for a long time. From a long-term perspective, the current stock market is in a good risk-return range. In the future, we will still strive to find value in high-quality stocks and dig out more' stones'. We don't have the reliable ability to accurately predict the short-term trend of the market, but focus on patiently collecting excellent companies with great prospects, waiting for the realization of the company's own value creation and the periodic return of market sentiment at some point in the future. "